Good day, and welcome to the Repligen Corporation's Third Quarter 2020 Earnings Conference Call. My name Danielle, and I will be your coordinator. All participations will be in listen-only mode. [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions. In order to accommodate all individuals who wish to ask questions there will be limit of two questions at a time. I would now like to turn the call over to your host for today's call, Sondra Newman, Head of Investor Relations for Repligen. Please go ahead.

Thank you, Danielle. Good morning to all of our participants. We really appreciate you joining our call. This morning we'll cover financial results and business highlights for three and nine months period ended September 30, 2020. We’ll also provide revised financial guidance for the year 2020. President and CEO, Tony Hunt, will cover business updates; and our CFO, Jon Snodgres, will cover our financial results and guidance. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risks related to our business is included in our annual report on Form 10-K, our quarterly reports on Form 10-Q, the current report on Form 8-K, which we filed this morning and other filings that we make with the SEC. Today’s comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not obligate or commit itself to update forward-looking statements, except as required by law. During this call, we’re providing non-GAAP results and guidance. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen’s website and on sec.gov. The non-GAAP figures in today’s report include the following: revenue growth at constant currency, gross profit and gross margin, operating expenses including R&D and SG&A, operating income and operating margin, income tax expense, net income and earnings per share as well as EBITDA and adjusted EBITDA. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to better enable investors to benchmark Repligen’s current results against historical performance and the performance of peers when evaluating investment opportunities. Now, I’ll turn the call over to Tony Hunt.

Thank you, Sondra, and good morning everyone. Quarter three was another outstanding quarter for the company as we continue execute on both the financial and strategic goals. The effort from our global team through the first nine months of 2020 has been exceptional. As demand has accelerated we are focused on increasing capacity across many sites delivering on key R&D programs and executing on three acquisitions. To support our continued growth we added towns across the organization and we are now approaching at 13,000 full-time employees, a 30% increase since January 1. In terms of overall revenue growth, our business has delivered over 35% growth in the quarter,, including 31% organic growth to reach $94.1 million driven by strong demand from COVID and gene therapy programs. We estimate that COVID programs accounted for approximately 55% of our revenue growth for the third quarter and 35% to 40% of our revenue growth through the first nine months. While non-COVID related growth was approximately 16% during the quarter and 17% to 18% for the year to date. So really strong 2020 thus far, and we're really proud to be involved in the hard-working done worldwide to fight the pandemic. From an orders perspective, total orders were approximately 80% in Q3 with COVID programs accounted for approximately half of this increase. Through the first nine months order growth was greater than 50% with COVID programs again accounting for approximately 40% of the increase. Based on continued strong performance in our core markets and increased demand from COVID customers, we now expect to end the year with overall revenues up 29% to 30% and organic growth in the range of 23% to 24% with a strong order load heading into 2021. As you saw last week, we've also executed on our strategic goals with…

Thank you, Tony. And good morning everyone. Today, we are reporting our financial results for the third quarter of 2020, as well as updating our financial guidance for the year. Unless otherwise mentioned, all financial measures discussed reflect adjusted non-GAAP measures. As you've seen in our press release this morning, we delivered record quarterly revenue and strong earnings growth in the third quarter of 2020, supported by continuing market strength and the positive impact we are seeing from COVID vaccine and therapeutic programs. As a continuation of realizing our vision of technology, leadership and bioprocessing, we completed the acquisitions of EMT on July 13, and NMS on October 20. On October 27, we also announced the pending strategic acquisition of ARTeSYN Biosolutions, which we expect will close in mid to late November. We've not yet included in our 2020 guidance, as the close of the deal is still pending. We expect the ARTeSYN acquisition to deliver revenue in the range of $33 million to $36 million in 2021, with three year revenue synergies in the range of $8 million to $10 million. We also expect ARTeSYN to return a positive return on invested capital of greater than 10% in five years. The financial impact of our EMT acquisition, which closed in Q3 is included in today's third quarter results, and the impact from the NMS deal that closed in Q4 is included in today's financial guidance. Now moving to specifics on our third quarter financial results. On our top line, we delivered record revenue of $94.1 million, representing 35% reported and 31% organic growth. Within the quarter we recognize nearly three points of non-organic growth from our EMT acquisition and a one to two point foreign currency tailwind. Overall, in the third quarter, we achieved a 9% consensus beat on…

We will now begin the question and answer session. [Operator Instructions] Your first question come from Dan Arias of Stifel. Please go ahead.

Good morning, guys. Tony, I'd like to start in maybe a predictable place and ask, if you can just sort of expand upon the way in which demand is involved from the COVID vaccine manufacturers when you look at Protein A and chrome and filtration. You made the comment on OPUS, so thank you. But what should we look for when we think about mix as we go from Phase 3 to hopefully some commercialization here on the higher profile projects? And then at the other end,are you able to sort of talk to that, I guess, you call the tail of the curve? I think the WHO had a 150 preclinical vaccine programs in the works the last time we checked. So how do you think about that opportunity? And them, I guess lastly, how does COVID work look within the context of the 100% order growth that you mentioned in terms of the magnitude and when that translates to revenues? So, starting off with a bunch there. So thanks.

Okay. Thanks, Dan. Yes. Probably the best way to look at this is from a revenue point of view and from an order point. I'll say from a revenue point of view, most of the growth we saw in the quarter really came from our filtration franchise. It was growth from some of the other and this is COVID growth. Our COVID impact was really in the filtration franchise started to pick up some activity on pre-packed columns. I think from an order perspective it was across the board, right? When you look at our proteins business, our filtration business, our chromatography business, and actually even our analytics business, we're beginning to see orders come through as we sort of went through Q3, sort of mid Q3 on and even into Q4 has been a real increase on the order side and it's across the board. It's not just one out one franchise that's seeing the orders. So that's a healthy sign as we go into 2021. In terms of how this all plays out in 2021? I think we'll know a lot more when we get to the end of the year and early next year. I think by the time we get to our February call, a lot of the early players on the vaccine side and the folks that are moving forward on the therapeutic side will at least have gone through Phase 2, Phase 3. So we have some ideas about where the companies we're working with what that could translate into for next year. Our estimate right now is, if you look at what we're thinking for 2020, we think about 10% of our revenue. And if you take the midpoint of our new guidance, about $35 million will come from COVID. We see that as potentially doubling next year. So an incremental, say $15 million to $30 million or $15 million to $35 million next year. So it's going to be somewhere in that range. But it kind of depends on where these vaccines play out and where the therapeutics play out. In terms of the tail, I think -- we view that as just more activity, right? And so there definitely is early activity with folks who are in that Phase 1, preclinical Phase 1 on vaccines, but we're nowhere close to addressing that total number. We're working with accounts we've always worked with. I think we'll pick up some revenue next year on those programs, but it will probably be modest. And most of the incremental revenue on COVID will probably come from the players that have moved forward quickly on vaccines and therapeutic programs here in 2012.

Yep. Okay, helpful. Maybe on the non-COVID side of the equation, it seems like demand there is, at the very least tracking in line with your expectations. We were listening to a webinar yesterday on gene and cell therapy, and the speaker from the FDA kind of made a comment about capacity for some of these manufacturing sites being ready for sort of the mid sized patient populations. But as you start to push above 100,000 patients per year, so it would probably require some sort of scale up. Do you have a view on where the industry is in terms of just accommodating larger patient populations and the potential step up in production. And what that might mean for you guys if you think that, that's something that's necessary?

Yes. Maybe start with the first part of your question. I think, overall, our non-COVID markets have done really well. I think part of the commentary that I made in my opening remarks was really to point that it's been a solid year in terms of performance in mAbs, biosimilars, gene therapy, gene therapy is up over 30% year to date, and that's where it'll finish by the end of the year for us. In terms of scale, I think it's still very much a split between some of the big players on the gene therapy side doing their own manufacturing or partnering with CDMOs. And then you have CDMOs, like Brammer and Catalent, the prior part of Catalent, all doing a ton of work in the gene therapy space and there are other players jumping in. So I think it just comes down to what the capacity expansion plans are at the CDMO level. And which companies that are bigger gene therapy companies are considering to sort of go it alone or build out their own manufacturing capacity. So, I think its probably a good question for the CDMOs as to how fast they feel they're going to ramp. But from what we're seeing right now, it's very active, there appears to be good capacity. But I'm sure as more drugs come through from Phase 1 to Phase 2, Phase 3 it will put some pressure on manufacturing. But so far, we haven't seen any sort of slow down there.

Okay. Thanks much, Tony. Appreciate it.

The next question comes from Puneet Souda of SVB Leerink. Please go ahead.

Yes. Hi, Tony. Congrats on the quarter. Great to see the growth and the order book here. First one if I could, on the -- sort of when you think about long term outlook traditionally, we have thought about a mid teens type of growth. But as see C Tech and EMT now with ARTeSYN and NMS and a number of these acquisitions. Is that the still the right way to sort of think about the business? Obviously, significant tailwinds for you in 2021 from COVID. But just thinking about the base business and how you're building that would love to sort of get thoughts on long term there? And then secondly, on the portfolio that you're building with EMT and ARTeSYN and NMS. And could you just walk us through what -- how does that fit into the long term strategy for Repligen offering the products and sort of comprehensive suite of offerings and attracting the customer, or making the customer more -- essentially, purchasing more and more products from you and more solutions. Could you walk through that?

Yes, sure. Maybe start with the -- I'll start with the last part of the question. On the EMT, ARTeSYN, NMS, as we looked at our systems business at the beginning of 2020, we really believe that we had a very differentiated portfolio, which came really from the from the spectrum acquisition back in 2017. We could see real traction with our TFDF technology. We could see the success of our hollow fiber business and the associated system sales. And I think it was over about a year and a half, two years ago, I talked about the fact that we would build out a systems team within Repligen. We've done that. We've invested a lot in our systems manufacturing, especially in Marlborough. So we felt that as we move forward, there were pieces of the workflow that we were still missing. So EMT gives us the silicone piece, the overmoulding piece, and it fits very nicely into what we call ProConnex at Repligen, and that sort of kind of our fluid management flow path, very much associated with hollow fibers. But by having the EMT component, we have a lot more control over our supply chain. That should ultimately lead to shorter lead times for our customers. NMS is a company we're also very familiar with. They're excellent at plastic fabrication. They do a lot of the bottle top assemblies. And so when you look at the fluid management, again, you really do need those components in fluid management. And then the final piece of the puzzle was, we could see that we were doing well with our hollow fiber business. We currently have seen very good traction with our flat sheet cassette business, but we didn't really have systems to wrap around that or even around our OPUS portfolio. And so with ARTeSYN they bring to the table, chromatography skids, filtration skids that are single use. Again, they have single use flow path assemblies. They work actually very closely with EMT. So there's a nice synergy there. And now, we just have a broader portfolio that we see as a good portfolio in the marketplace. It gives us a lot more flexibility. We can start to integrate the FlowVPE technology from C Tech into some of these skids, especially in chromatography and filtration. So a lot of exciting steps ahead. But obviously, we have to get to closing the deal first and 2021 will be around really the commercial and operational integration. And I expect to see new products, probably 2022/2023 timeframe. Remind me again, Puneet, the first part of the question.

Long term mid teens.

Yes. So on the long term growth, I mean, clearly, over the last couple of years we've been signaling that with the investments we're making an R&D and the new products that are coming through, we feel like we would be at the mid to high end of our long term growth of 10% to 15%. We clearly have moved into that space. We're going to take a look at it at the end of the year. And when we get to the February call, and just really start to see what we think is the sort of future longer term growth. But we've clearly inched up. We're no longer 10%, 12%, 13%. We're in a higher organic growth range than what we've seen historically. And I think with some of these acquisitions, this really helps us for the future. On top of that, it's a little tricky on COVID, because you're not going to really know what the impact of COVID is going to be until we see where some of these clinical trials go. So I think the February timeframe should work actually quite nicely, because at that stage we'll understand a little bit more about the demand and be able to give a little firmer sort of percentage of growth that we might anticipate in 2021.

Okay, great. And the last one, if I could squeeze in on the COVID-19 affinity ligand. Could you speak to the significance of that? And if you could explain whether how it's going to be integrated into the workflow? Obviously, this is in 2021. Some projects are already ramping up. Is it fairly easy to integrate into that at that point? And sort of the capacity built out for it. It appears that this is going to be used in the -- essentially manufacturing and production. So I just wanted to get a sense on the capacity? And if you could provide any expectations around what the contribution for this could be in 2021? Appreciate it. Thank you.

Yes. Probably little early, Puneet to really figure out what the impact might be of the ligand and the resin. Clearly, our partners Navigo have done a great job of identifying targets and figuring out the, what the right ligand structure needs to be for spike protein. So that's been obviously very positive. We've been ramping very quickly to scale up ligand manufacturing, and then move to the resin manufacturing component of this. So expect that we will have a resin on the market beginning of next year. I think it's going to be hard for us to jump into commercial processes or close to commercial processes. I think it's going to be more next gen versions of vaccines that we'll be able to be evaluated for. And so I think revenue for 2021 is going to be very modest. I think it's going to be more evaluations. And if we are successful with this, I think you'll see revenue really in the 2022 timeframe.

Good. That's very helpful. Thank you.

The next question comes from John Kreger of William Blair. Please go ahead.

Hi. Thanks very much. Tony, you talked about kind of 80% to 100% order growth. I'm guessing that's above what you were planning a few months ago. Can you just give us an update on how your capacity increased plans have changed? And where do you see the biggest sort of wait time challenges in your order book at this point?

Yes. So, no doubt the order growth really accelerated. And it's really been from sort of mid Q3 on. It was it was really tracking to where we were expecting right up until probably middle of August. So really the last five, six weeks of the quarter has been exceptionally strong and upheld even into Q4. It is across the board. I think we're no different as a buyer processing company versus anyone else in our industry. I think everybody is stretched to get product out the door. The demand has gone up significantly. So every product line in our portfolio, we're pushing, we're adding more people, we're, we're expanding. So there's no one product line where you're looking at it saying, we have to do major capital expansion. I think for us, last year it was a good year in the sense that we really expanded on OPUS. We did expand on our flat sheet cassette business with a brand new facility in 2019. We have plans to expand over in Rancho starting this year. So that's kind of in line with what we wanted to do. But everybody in our industry is definitely stretched. We're stretched. We're pushing. Our people are working seven days a week, basically all shifts as we try and keep up with existing demand and also keep up with the demand for COVID. So, hats off to our employees. They've been exceptional.

Great, thanks. And maybe any kind of early comments on what you'd like to accomplish in 2021 in terms of new product flow. I know you had a very busy year this year on the new product front? Thanks.

Yes. I think on the new product side, it's a little early, John, to say, we're going to have X and Y coming through. I think all the work we've done this year to get whether it's next gen controllers out for ATF to FlowVPE, next gen for C Tech, to what we've done on the flat sheet cassettes and what we're doing on the ligand side, and what we're doing with TFDF. They are still brand new products. So I think a lot of our focus next year will still be on making those products a success. There's clearly other activities going on in R&D. We haven't really spoken about it. So maybe in February, we'll talk a little bit about plans for 2021. But I would expect if I just fast forward three or four months, I would think that there'll be three priorities for next year. One, all the products we've developed this year, we've got to double down and make sure they're successful in the marketplace. Two, we've got to make sure we have the right capacity to meet the demand for COVID and existing customers. And then the third one will be the integration of the three deals that we've done. So making sure that we continue to work very closely with leadership that EMT, NMS and then ARTeSYN to get off to the right start and hit the targets that we set for ourselves in 2021.

Sounds good. Thank you.

The next question comes from Tyco Peterson of JP Morgan. Please go ahead.

Hi, good morning. This is Julia on for Tyco. Thanks for taking the question. Tony, I was wondering if you could talk a little bit About the bioprocessing industry capacity built and the expected pace of future expansions over the next year or so. Obviously, we've yet to see approvals and commercial scale-up for the vaccines. But many manufacturers have committed capacity at risk already. So just wondering how are you thinking about incremental industry capacity expansion from here? And then, to what extent is your growth levered to these upfront capacity built versus ongoing production on the consumable side? Thank you.

Yes. Julia, look, a really good question. I don't think we're any different than any of the other players in our industry. We're all investing in terms of capacity. We're going to spend $30 million plus this year. We're going to have probably above that in spend next year. We'll obviously talk about that in a couple of months. But every single business in our portfolio we've assessed in 2020, we've done that as well in 2019. So plans to double and triple capacity. They're all in place. And we're working towards those. So, for me, I think this is an incredibly healthy industry bioprocessing. And regardless of what happens with COVID, I just think that as an industry, we all have to invest in capacity, and it becomes a really important part of what each and every bioprocessing company is doing. So for me, it's around making sure we have the right capacity for our pre-packed columns, right capacity -- future capacity for our filtration, franchises, same thing on proteins, same thing on analytics. So, we're fully committed to investing. And we think that growth is there, no matter what happens with COVID. We think this is a very healthy market. We think gene therapy is really good. We think we're very well positioned. We think the acquisitions we've done strengthens where we're going. And I don't think there's really any risk to us increasing capacity. It's a matter of just making sure we get it done quickly.

Okay. And then do you believe the pandemic has permanently accelerated the adoption of single use technologies? Or do you see the industry likely reverting to the digital stainless steel equipment for large scale production once we settle on a few winning vaccines? And what are the implications of either scenario for your business?

Yes. I don't think COVID vaccines has accelerated the adoption of single use. I think single use has been the primary driver of growth within bioprocessing and at our account -- the top accounts, whether it's the Big Pharma or it's the CDMO. So that whole trend of single use technology has been there. There's clearly, you're going to have vaccine manufacturers that are using single use. And you're going to have vaccine manufacturers that are stainless steel, depending on what facilities they want to work with. So, I think COVID is an important part of what's going on. I think it's clearly a driver of growth for the industry over the next few years. But I think the single-use train has been already on the tracks for a few years. I think it's going to continue to move forward. I think customers will continue to want single-use technology, single-use flow paths. I think it's a healthy spot for everyone in bioprocessing right now.

Got it. And just lastly from me, one of your peers who reported recently know that some customer inventory buildup. So just wondering if you're seeing a similar dynamic?

Yes. That's a hard one to answer. Simply because we don't really know how much of it is going into inventory and how much of it is being used straightaway. So, I think the better way maybe to look at that is that, I think customers are ordering further out than where they've done and what they've done before. So in other words, if a company really was looking at ordering out two to three months in advance, I think we're definitely seeing customers ordering out four to six months in advance. So we -- a lot of the orders we've taken in Q3 and here in Q4 are definitely going into Q1 2021.

Got it. Very helpful. Thank you.

The next question comes from Jacob Johnson of Stephens. Please go ahead.

Hey. Thanks for taking the questions and congrats on the quarter. Just Tony, going back to the order growth commentary, 100% order growth in your direct product portfolio. How should we think about the timing of realizing those orders? Maybe what are the lead times on these orders? And should we think of these maybe flowing through revenues in the first half of next year rather than the fourth quarter?

Yes. I mean, I think the way to look at it is -- a significant chunk of that is going into Q1 and early Q2 2021. Obviously, there's orders that have come through in Q3 that are going to be for Q4. So I think you should look at our guidance in terms of where we're going to finish for revenue. And that's a pretty good range for us. There may be potentially a little bit of upside to that. But that will come from just timing of when people want product delivered. So if -- right now, you might have something that's sitting in January and the customer is asking to get it delivered early, we'd love to do that. But in general, I'd say more of those orders are slated for Q1.

Got it. And then maybe a bigger picture question. You bought EMT and NMS this year, I think Repligen was a customer of both. Can you just talked about the strategy to vertically integrate here? Is this about ensuring the supply of critical components in a tight bioprocessing market? Or is there also just a component that these are kind of opportunistic deals that fill in some gaps in your portfolio?

Yes. It's a bit of both, I think. There's no doubt that that owning your supply chain, especially for critical components is a really -- it's a good thing to have in your portfolio. So we really like what EMT and NMS bring to the table. EMT becomes a very important part of what we're doing or we'll do in the future with ARTeSYN. So that that is an important part of our thinking on this. And then there is an opportunity because both companies sell to companies like Repligen other companies in our space, other bioprocessing companies. And so there's an opportunity here to continue to build off all the good things that EMT and NMS have done over the last five, 10 years. And with a little bit of effort on the commercial side, I think we can continue to grow those business as businesses while still benefiting ourselves from having control over supply chain, and hopefully driving down to shorter lead times for customers.

Got it? Thanks for taking the questions.

[Operator Instructions] The next question comes from Matt Hewitt of Craig Hallum Capital Group. Please go ahead.

Good morning and congratulations on a very strong quarter. One question for me. And it's kind of a two part. But with 10% of your revenues coming from COVID, how should we be thinking about the durability of that opportunity? I realize you don't have a crystal ball. But are you expecting that this is going to have a little bit longer tail as the vaccines get out and possibility of that becoming an annual opportunity? And then as far as the capacity is concerned, and you address this a little bit, but you've added space, you've added some shifts. Are you right now staying ahead of the demand? Or in some ways you're playing a little bit of catch up? And what kind of flexibility do you have with that capacity as we get into later next year, and maybe into 2022? Do you have the ability to kind of scale back in some areas and add capacity in others depending upon the volumes for the products that you're seeing? Thank you.

Yes. On the revenue side, the COVID impact, obviously, we think it'll be around 10% of our total revenues for the year. It's hard to tell what that really will translate into in 2021. But we think there's an incremental sort of $15 million to $35 million or $20 million to $35 million of revenue on top of that $35 million in 2021. But that depends a lot on where -- of where these vaccines and therapeutic programs go in the next three or four months. So crystal ball is hard, because I think we just have to wait it out. And I think the February earnings call be a good time to just say what we think that's going to be in 2021. But that's at least our best guess right now as an incremental sort of $15 million to $35 million in 2021. In terms of capacity, as I said earlier, we're definitely adding people, bringing in equipment, expanding and we're doing exactly what everybody else in bioprocessing is doing. Everybody is pushing really, really hard. There's no doubt that lead times are going out a little bit, because the demand is so high. But also we have a program in place across all our businesses where we are trying to get ahead of this and expect by sort of mid next year, places where we were maybe a little bit behind we should be ahead. So it's like six months to eight months of a lot of investment that has to happen and then hopefully at the back end of that you get that sort of pressure relief valve and you have a lot more capacity to deal with increased demand over the following years. So that's kind of the way we're looking at it.

Understood. Thank you.

The next question comes from Brandon Couillard from Jefferies. Please go ahead.

Hi. This is Matt on for Brandon this morning. Thanks for taking the question. Tony, one for you on the new products that you mentioned earlier, this year has been a busy one for Repligen. Last quarter, you talked about some of the challenges in a COVID world in terms of customers evaluating these products. If we look out to next year assuming things improve or start to normalize, is there an opportunity for some pent-up demand for some of the new products you've had here in 2020. And then, as we start to think about next year, any color you can provide on what you're penciling in for a contribution from these in 2021? Thank you.

Yes. So I think in terms of new product impact, there's no magic formula here in terms of you launch product, and all of a sudden you get this massive ramp in demand. So technology like TFDF, which we launched in 2019 has done really well. And it's tracking maybe a little bit ahead of where we thought it was going to be, but not dramatically ahead. So it's a process, right? If you've got a good product out there, you're going to pick up a couple of million dollars of revenue in the first full year that you're out in the marketplace. So, when I look at the new products we have right now, they're probably going to 1% to 2% probably is a good range to think about in terms of what their impact would be in 2021. Because it takes a while for new products to get adopted. And these products will be still selling them to customers 15 years from now. So it's not like we launch it and then four years from now that the product is gone away, because it's obsolete. These products tend to stay in the market for quite a while. So early days. I don't see it as a huge impact next year, maybe one to two points of growth. And then the other part Matt, I'm sorry.

Is just around -- last quarter you talked a little bit about some of the challenges in terms of customers evaluating these products. Is there any kind of pent-up demand you pick up next year as return -- hopefully return to a more normalized environment?

I think that the -- I think COVID has forced us to be more quality than quantity in terms of evaluation. So we've had to really pick and choose the -- and work with the accounts that are really want to implement technology. So that that's really what's happened this year. I think our R&D teams, unfortunately we've had -- a lot of our team has worked from home through -- especially through the spring and early summer. People have come back that's why our percent of sales and R&D spend is lighter than what you might have anticipated. Expect that'll go up next year. Expect that things will open up more. It definitely has opened up since the summer. Hard to tell right now, if kind of the second wave that's going through Europe, how that impacts us in Q4 from an evaluation point of view. But we're going to be dealing with these waves and companies allowing people in or not allowing people in probably for the next 12 months.

Thank you.

This concludes a question and answer session. I would like to turn the conference back over to Tony Hunt for final remark.

Yes. Just like to thank everybody for joining us this morning. Obviously, a lot going on. We've had a tremendous Q3 looking strong for the year. I just want to take a moment to thank our employees. I mean the work that this team is doing, especially during COVID to get products out the door to meet the demand of customers has really been exceptional. So look forward to finishing off the year and catching up with everybody in the February timeframe.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.